JPH09507856A - ピリジルイミダゾール誘導体およびその製造方法 - Google Patents
ピリジルイミダゾール誘導体およびその製造方法Info
- Publication number
- JPH09507856A JPH09507856A JP8501959A JP50195996A JPH09507856A JP H09507856 A JPH09507856 A JP H09507856A JP 8501959 A JP8501959 A JP 8501959A JP 50195996 A JP50195996 A JP 50195996A JP H09507856 A JPH09507856 A JP H09507856A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pyridine
- tetrazol
- imidazo
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 16
- 239000001257 hydrogen Substances 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 6
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 180
- -1 alkyl radical Chemical class 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003254 radicals Chemical class 0.000 claims description 10
- 239000007800 oxidant agent Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 230000001590 oxidative effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- 150000003536 tetrazoles Chemical group 0.000 claims description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 2
- GRHZLQBPAJAHDM-SPRQWYLLSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound CC1=CC=CC(C)=C1OCC(=O)N[C@H]([C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 GRHZLQBPAJAHDM-SPRQWYLLSA-N 0.000 claims description 2
- 125000005466 alkylenyl group Chemical group 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 abstract description 8
- 101800000733 Angiotensin-2 Proteins 0.000 abstract description 8
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract description 8
- 229950006323 angiotensin ii Drugs 0.000 abstract description 8
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000700157 Rattus norvegicus Species 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000004531 blood pressure lowering effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 102000008873 Angiotensin II receptor Human genes 0.000 description 5
- 108050000824 Angiotensin II receptor Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 206010038464 renal hypertension Diseases 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007515 enzymatic degradation Effects 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 229960003883 furosemide Drugs 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 125000000815 N-oxide group Chemical group 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- RIUUIBYVQFKOLB-UHFFFAOYSA-N (6-bromo-2-butyl-1h-imidazo[4,5-b]pyridin-5-yl)methanol Chemical compound BrC1=C(CO)N=C2NC(CCCC)=NC2=C1 RIUUIBYVQFKOLB-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- NRVIZYWYHXROKA-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=NC2=N1 NRVIZYWYHXROKA-UHFFFAOYSA-N 0.000 description 1
- JYWWGZAAXTYNRN-UHFFFAOYSA-N 3-bromo-6-methylpyridin-2-amine Chemical compound CC1=CC=C(Br)C(N)=N1 JYWWGZAAXTYNRN-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- CRELZBHEKSIUDR-UHFFFAOYSA-N 5-bromo-6-methyl-3-nitropyridin-2-amine Chemical compound CC1=NC(N)=C([N+]([O-])=O)C=C1Br CRELZBHEKSIUDR-UHFFFAOYSA-N 0.000 description 1
- XFHAYQGHHKCVBA-UHFFFAOYSA-N 5-bromo-6-methylpyridine-2,3-diamine Chemical compound CC1=NC(N)=C(N)C=C1Br XFHAYQGHHKCVBA-UHFFFAOYSA-N 0.000 description 1
- MAXSLAYVXPZFOD-UHFFFAOYSA-N 6-bromo-2-butyl-1h-imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound O=CC1=C(Br)C=C2NC(CCCC)=NC2=N1 MAXSLAYVXPZFOD-UHFFFAOYSA-N 0.000 description 1
- JDMOVKKORWPLSS-UHFFFAOYSA-N 6-bromo-2-butyl-5-(dimethoxymethyl)-1h-imidazo[4,5-b]pyridine Chemical compound COC(OC)C1=C(Br)C=C2NC(CCCC)=NC2=N1 JDMOVKKORWPLSS-UHFFFAOYSA-N 0.000 description 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 244000085692 Cordia alliodora Species 0.000 description 1
- 235000004258 Cordia alliodora Nutrition 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical class C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- FVTRDWMTAVVDCU-UHFFFAOYSA-N acetic acid;hydrogen peroxide Chemical compound OO.CC(O)=O FVTRDWMTAVVDCU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- NYHHCJRPBREZHE-UHFFFAOYSA-N hydrogen peroxide;2,2,2-trifluoroacetic acid Chemical compound OO.OC(=O)C(F)(F)F NYHHCJRPBREZHE-UHFFFAOYSA-N 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- BDGDWWGTAFXEEW-UHFFFAOYSA-N methylsulfinylmethane;oxalyl dichloride Chemical compound CS(C)=O.ClC(=O)C(Cl)=O BDGDWWGTAFXEEW-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1。 下記式(I)のピリジルイミダゾール化合物およびその薬理学的に許容可 能な塩: 式中、 Aは直鎖、分枝鎖または環状C1−C6アルキルまたはアルケニル基、OR1( ここで、R1は水素、または直鎖、分枝鎖または環状C1−C6アルキルまたはア ルケニルラジカルである)、またはNR2R3(ここで、R2およびR3は独立的に 水素、または直鎖、分枝鎖または環状C1−C6アルキルラジカルである)であり ; Bは下記式 の基であり、 Dは水素;ハロゲン;OH、C1−C4アルコキシラジカル、CO2R1、COR1 、CON(R1)2またはN(R1)2(ここで、R1は前記定義した通りである) で任意に置換された直鎖、分枝鎖または環状C1−C6アルキル、C2−C6アルケ ニルまたはC2−C6アルキニル基;テトラゾール−5−イル;ペルフルオロ−C1 −C4アルキル基;またはN(R1)2、OR1、CO2R1またはCON(R1)2 (ここで、R1は前記定義した通りである)であり; Eは水素;ハロゲン;OH、C1−C4アルコキシラジカル、CO2R1、COR1 、CON(R1)2またはN(Rt)2(ここで、R1は前記定義した通りである ) で任意に置換された直鎖、分枝鎖C1−C6アルキル、C2−C6アルケニルまたは C2−C6アルキニル基;ペルフルオロ−C1−C4アルキル基;NO2;またはN (R1)2またはOR1(ここで、R1は前記定義した通りである)であり;および nは0または1ないし4の整数である。 2。 Aが直鎖、分枝鎖または環状C2−C6アルキル基またはOR1(ここで、 R1は直鎖、分枝鎖または環状C2−C5アルキルラジカル)であり、 Bが下記式 の基であり、 Dが水素;OH、C1−C2アルコキシラジカル、CO2R1、COR1またはN (R1)2(ここで、R1は前記定義した通りである)で任意に置換された直鎖、 分枝鎖または環状C1−C4アルキルまたはアルケニル基であり、 Eが水素、または直鎖、分枝鎖または環状C1−C4アルキルまたはアルケニル 基であり、 nが0、1または2である請求項1に記載の化合物。 3。 下記化合物からなる群から選ばれた請求項1に記載の化合物: 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−2−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−2−メチル−ピリジン−6−イル )−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメ チル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−3−メチル−ピリジン−6−イル ) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−4−メチル−ピリジン−6−イル )−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメ チル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−3−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−4−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−2−メチル−ピリジン−3−イル )−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメ チル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−6−メチル−ピリジン−3−イル )−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメ チル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−ピリジン−2−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−(2−ヒドロキシエチル−1−イル)−6−(1−オキシ−ピ リジン−2−イル)−3−[2′−(1H−テトラゾール−5−イル)−ビフェ ニル−4−イルメチル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メトキシカルボニル−6−(1−オキシ−ピリジン−2−イル )−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメ チル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−(N,N−ジエチルカルバモイル)−6−(1−オキシ−ピリ ジン−2−イル)−3−[2′−(1H−テトラゾール−5−イル)−ビフェニ ル−4−イルメチル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−6−(1−オキシ−ピリジン−2−イル)−3−[2′−(1H− テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H−イミダゾ[ 4,5−b]ピリジン; 2−ブチル−5−(N,N−ジメチルアミノ)−6−(1−オキシ−ピリジン− 2−イル)−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4 −イルメチル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−エチル−6−(1−オキシ−ピリジン−2−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−フルオロ−6−(1−オキシ−ピリジン−2−イル)−3−[ 2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3 H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−2−イルメチル)−3 −[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル] −3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−3−イルメチル)−3 −[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル] −3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−[2−(1−オキシ−ピリジン−2−イル)エチ ル−1−イル]−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル −4−イルメチル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−[2−(1−オキシ−ピリジン−3−イル)エチ ル−1−イル]−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル −4−イルメチル]−3H−イミダゾ[4,5−b]ピリジン; 2−エチル−5−メチル−6−(1−オキシ−ピリジン−2−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−エトキシ−5−メチル−6−(1−オキシ−ピリジン−2−イル)−3−[ 2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]− 3H−イミダゾ[4,5−b]ピリジン; 2−プロピル−5−メチル−6−(1−オキシ−ピリジン−2−イル)−3−[ 2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3 H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−2−メチル−ピリジン −6−イル)−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル− 4−イルメチル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−ピリジン−4−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−ピリジン−3−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン;およびこれらの混合物。 4。 下記化合物からなる群から選ばれた請求項3に記載の化合物。 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−2−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6(1−オキシ−2−メチル−ピリジン−6−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−3−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−4−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−ピリジン−2−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メトキシカルボニル−6−(1−オキシ−ピリジン−2−イル )−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメ チル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−6−(1−オキシ−ピリジン−2−イル)−3−[2′−(1H− テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H−イミダゾ[ 4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−2−メチル−ピリジン −6−イル)−3−[2′−(1H−テトラゾール−5−イル)−ビフェニル− 4−イルメチル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−ピリジン−4−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−ピリジン−3−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン;およびこれらの混合物。 5。 下記化合物からなる群から選ばれた請求項4に記載の化合物。 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−2−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシ−ピリジン−3−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−メチル−6−(1−オキシーピリジン−4−イル)−3−[2 ′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチル]−3H −イミダゾ[4,5−b]ピリジン; 2−ブチル−5−ヒドロキシメチル−6−(1−オキシ−ビリジン−2−イル) −3−[2′−(1H−テトラゾール−5−イル)−ビフェニル−4−イルメチ ル]−3H−イミダゾ[4,5−b]ピリジン;およびこれらの混合物。 6。 (A)下記式(II)の化合物を式ACOOHのカルボン酸または式ACO ORのエステル(ここで、Aは請求項1で定義した通りであり、Rはメチルまた はエチルである)と縮合反応させて下記式(III)の化合物を得、 (B)式(III)の化合物を塩基の存在下で下記式(IV)の化合物と反応させて 下記式(V)の化合物を得、 (C)式(V)の化合物をテトラキス(トリフェニルホスフィン)パラジウム( O)の存在下で下記式(VI)の化合物と反応させて下記式(VII)の化合物を得 、(D)式(VII)の化合物を酸化剤で酸化させることを含む下記式(I′)の 化合物の製造方法: 式中、 Xはハロゲンまたはトリフルオロメタンスルホナートであり、 Mは離脱基であり; Pはテトラゾール保護基であり; mは0であり; n′は0であり; A、B、DおよびEは請求項1で定義した通りである。 7。 (A)下記式(II)の化合物を式ACOOHのカルボン酸または式ACO ORのエステル(ここで、AおよびRは請求項6で定義した通りである)と縮合 反応させて下記式(III)の化合物を得、 (B)式(III)の化合物を塩基の存在下で下記式(IV)の化合物と反応させて 下記式(V)の化合物を得、 (C)式(V)の化合物をテトラキス(トリフェニルホスフィン)パラジウム( O)の存在下で下記式(VI)の化合物と反応させて下記式(VIII)の化合物を得 、 (D)式(VIII)の化合物をオゾンで酸化させて式(IX)の化合物を得、 (E)式(IX)の化合物を下記式(X)の化合物と反応させて下記式(XI)の化 合物を得、 (F)式(XI)の化合物をメタンスルホニルクロリドと反応させて式(XII)の化 合物を得、 (G)式(XII)の化合物を水素化トリブチルスズで還元させて下記式(VII)の 化合物を得、そして (H)式(VII)の化合物を酸化剤で酸化させることを含む下記式(I′′)の 化合物の製造方法: 式中、 B、D、E、M、PおよびXは請求項6で定義した通りであり; mは0または1であり;および n′は1である。 8。 (A)下記式(II)の化合物を式ACOOHのカルボン酸または式ACO ORのエステル(ここで、AおよびRは請求項6で定義した通りである)と縮合 反応させて下記式(III)の化合物を得、 (B)式(III)の化合物を塩基の存在下で下記式(IV)の化合物と反応させて 下記式(V)の化合物を得、 (C)式(V)の化合物をテトラキス(トリフェニルホスフィン)パラジウム( O)の存在下で下記式(VI)の化合物と反応させて下記式(VIII)の化合物を得 、 (D)式(VIII)の化合物をパラジウム触媒の存在下で水素化反応させて式(VI I)の化合物を得、そして (E)式(VII)の化合物を酸化剤で酸化させることを含む下記式(I′′′)の 化合物の製造方法: 式中、 B、D、E、M、PおよびXは請求項6で定義した通りであり; mは1であり;および n′は2である。 9。請求項1に記載のピリジルイミダゾール化合物の治療有効量および薬剤学的 に許容可能な担体を含む医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR19940013163 | 1994-06-11 | ||
KR1994/13163 | 1995-05-08 | ||
KR1019950011100A KR0151819B1 (ko) | 1994-06-11 | 1995-05-08 | 신규의 피리딜 n-옥사이드로 치환된 피디딜이미다졸 유도체 및 그의 제조방법 |
KR1995/11100 | 1995-05-08 | ||
PCT/KR1995/000075 WO1995034564A1 (en) | 1994-06-11 | 1995-06-07 | Pirydyl imidazole derivatives and processes for the preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09507856A true JPH09507856A (ja) | 1997-08-12 |
JP2903260B2 JP2903260B2 (ja) | 1999-06-07 |
Family
ID=26630434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8501959A Expired - Fee Related JP2903260B2 (ja) | 1994-06-11 | 1995-06-07 | ピリジルイミダゾール誘導体およびその製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5691348A (ja) |
EP (1) | EP0765328B1 (ja) |
JP (1) | JP2903260B2 (ja) |
KR (1) | KR0151819B1 (ja) |
AU (1) | AU691307B2 (ja) |
CA (1) | CA2191947C (ja) |
DE (1) | DE69518647T2 (ja) |
ES (1) | ES2149995T3 (ja) |
WO (1) | WO1995034564A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0151819B1 (ko) * | 1994-06-11 | 1998-10-15 | 강박광 | 신규의 피리딜 n-옥사이드로 치환된 피디딜이미다졸 유도체 및 그의 제조방법 |
IL133800A0 (en) | 1997-07-03 | 2001-04-30 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
US6465484B1 (en) * | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
US8372862B2 (en) * | 2009-06-02 | 2013-02-12 | Korea Research Institute Of Chemical Technology | Pharmaceutical composition for preventing or treating osteoporosis or obesity comprising phenyltetrazole derivative |
WO2011134019A1 (en) * | 2010-04-30 | 2011-11-03 | The University Of Melbourne | Novel biphenyl sartans |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
MA54133B1 (fr) | 2018-03-08 | 2022-01-31 | Incyte Corp | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE64514B1 (en) * | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
US5332744A (en) * | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
IL94390A (en) * | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
IL96019A0 (en) * | 1989-10-31 | 1991-07-18 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
EP0434038A1 (en) * | 1989-12-22 | 1991-06-26 | Takeda Chemical Industries, Ltd. | Fused imidazole derivatives, their production and use |
EP0470543A1 (de) * | 1990-08-10 | 1992-02-12 | Dr. Karl Thomae GmbH | Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung |
US5066586A (en) * | 1990-08-20 | 1991-11-19 | Merck & Co., Inc. | Process for preparation of novel angiotensin II antagonists |
GB9201715D0 (en) * | 1992-01-28 | 1992-03-11 | Ici Plc | Chemical process |
KR0151819B1 (ko) * | 1994-06-11 | 1998-10-15 | 강박광 | 신규의 피리딜 n-옥사이드로 치환된 피디딜이미다졸 유도체 및 그의 제조방법 |
-
1995
- 1995-05-08 KR KR1019950011100A patent/KR0151819B1/ko not_active IP Right Cessation
- 1995-06-07 US US08/750,460 patent/US5691348A/en not_active Expired - Lifetime
- 1995-06-07 CA CA002191947A patent/CA2191947C/en not_active Expired - Fee Related
- 1995-06-07 WO PCT/KR1995/000075 patent/WO1995034564A1/en active IP Right Grant
- 1995-06-07 AU AU27538/95A patent/AU691307B2/en not_active Ceased
- 1995-06-07 JP JP8501959A patent/JP2903260B2/ja not_active Expired - Fee Related
- 1995-06-07 ES ES95922774T patent/ES2149995T3/es not_active Expired - Lifetime
- 1995-06-07 EP EP95922774A patent/EP0765328B1/en not_active Expired - Lifetime
- 1995-06-07 DE DE69518647T patent/DE69518647T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2903260B2 (ja) | 1999-06-07 |
US5691348A (en) | 1997-11-25 |
AU2753895A (en) | 1996-01-05 |
KR960000884A (ko) | 1996-01-25 |
WO1995034564A1 (en) | 1995-12-21 |
ES2149995T3 (es) | 2000-11-16 |
AU691307B2 (en) | 1998-05-14 |
DE69518647T2 (de) | 2000-12-28 |
CA2191947C (en) | 1999-06-15 |
CA2191947A1 (en) | 1995-12-21 |
EP0765328B1 (en) | 2000-08-30 |
KR0151819B1 (ko) | 1998-10-15 |
DE69518647D1 (de) | 2000-10-05 |
EP0765328A1 (en) | 1997-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3382963B2 (ja) | イミダゾピリジン類 | |
JPH04235974A (ja) | 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物 | |
US9518055B2 (en) | Imidazopyridyl compounds as aldosterone synthase inhibitors | |
JP2013532162A5 (ja) | 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および/または予防のためのその使用 | |
WO2007032466A1 (ja) | 複素環化合物、その製造方法並びに用途 | |
JPWO2012102297A1 (ja) | ピラゾロピリジン誘導体、またはその薬理学的に許容される塩 | |
EP0443568A1 (en) | Fused thiophene derivatives, their production and use | |
JPH05279360A (ja) | イミダゾピリジン | |
JP2023550444A (ja) | トリアジンジオン系誘導体、その調製方法及びその医薬的応用 | |
JPH09507856A (ja) | ピリジルイミダゾール誘導体およびその製造方法 | |
SK46793A3 (en) | Regenarative melting tank and method of working | |
EP2757883B1 (en) | Triazolopyridyl compounds as aldosterone synthase inhibitors | |
EP0743943B1 (en) | Pyridyl imidazole derivatives and processes for the preparation thereof | |
JP2641686B2 (ja) | 新規キノリン誘導体 | |
FI108135B (fi) | Menetelmä terapeuttisesti aktiivisten 7-okso-8-[2'-(1H-tetrasol-5-yyli)bifenyl-4-yylimetyyli]-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidiinijohdannaisten valmistamiseksi | |
CN114149423B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
KR100191898B1 (ko) | 벤조푸란계 치환기를 갖는 피리딜 이미다졸 유도체, 그의 제조방법 및 그를 함유하는 혈압강하제 | |
KR0156948B1 (ko) | 이소인다졸 화합물 | |
KR100191897B1 (ko) | 벤조푸란계 치환기를 갖는 피리딜 이미다졸 유도체, 그의 제조방법 및 그를 함유하는 혈압강하제 | |
JP2564785B2 (ja) | イミダゾピリジン誘導体及びその製法 | |
MXPA05006588A (es) | Compuestos de pirazol como derivados antagonistas del receptor de la integrina. | |
JPH0665235A (ja) | 新規イソインダゾール誘導体 | |
JPH06184149A (ja) | 新規イミダゾ[1,2−a]ピリジン誘導体 | |
JPH07196655A (ja) | 2h−インダゾール誘導体 | |
MXPA98002028A (en) | Quinolein-2 (1h) -ona derivatives as seroton antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080326 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090326 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100326 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |